Page 162 - Read Online

Sadaf et al. J Transl Genet Genom 2022;6:63-83 https://dx.doi.org/10.20517/jtgg.2021.36 Page 81

chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-6. PubMed
71. Lodé L, Eveillard M, Trichet V, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Haematologica 2010;95:1973-6. DOI PubMed PMC
72. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival
after conventional-dose chemotherapy. Blood 1998;92:802-9. PubMed
73. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe
Francophone du Myélome. Blood 2007;109:3489-95. DOI PubMed
74. Gmidène A, Saad A, Avet-Loiseau H. 8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor
suppressor genes in the pathogenesis of multiple myeloma. Med Oncol 2013;30:489. DOI PubMed
75. Pratt G. Molecular aspects of multiple myeloma. Mol Pathol 2002;55:273-83. DOI PubMed PMC
76. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol
2009;1:a000034. DOI PubMed PMC
77. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by
diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-30. DOI PubMed PMC
78. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell 2007;12:131-44. DOI PubMed PMC
79. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002;12:9-18. DOI
PubMed
80. Chng WJ, Gonzalez-Paz N, Price-Troska T, et al. Clinical and biological significance of RAS mutations in multiple myeloma.
Leukemia 2008;22:2280-4. DOI PubMed PMC
81. Patrawala S, Puzanov I. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncol 2012;8:509-23.
DOI PubMed
82. Bharti AC, Shishodia S, Reuben JM, et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from
multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004;103:3175-84. DOI PubMed
83. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature
1988;332:83-5. DOI PubMed
84. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-
activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in
myeloma cells. Br J Haematol 2000;109:823-8. DOI PubMed
85. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to
chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003;9:316-26. PubMed
86. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004;9:667-76. DOI
PubMed
87. Aronson LI, Davenport EL, Giuntoli SG, et al. Autophagy is a key myeloma survival pathway that can be manipulated therapeutically
to enhance apoptosis. Blood 2010;116:4083. DOI
88. Tasaka T, Berenson J, Vescio R, et al. Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma. Br J
Haematol 1997;96:98-102. DOI PubMed
89. Uchida T, Kinoshita T, Ohno T, Ohashi H, Nagai H, Saito H. Hypermethylation of p16INK4A gene promoter during the progression
of plasma cell dyscrasia. Leukemia 2001;15:157-65. DOI PubMed
90. Kassambara A, Gourzones-Dmitriev C, Sahota S, et al. A DNA repair pathway score predicts survival in human multiple myeloma:
the potential for therapeutic strategy. Oncotarget 2014;5:2487-98. DOI PubMed PMC
91. Neri P, Ren L, Gratton K, et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood
2011;118:6368-79. DOI PubMed PMC
92. Hu Y, Lin J, Fang H, et al. Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.
Leukemia 2018;32:2250-62. DOI PubMed PMC
93. Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in
multiple myeloma. Blood 2018;132:2456-64. DOI PubMed PMC
94. Marchesini M, Fiorini E, Colla S. RNA processing: a new player of genomic instability in multiple myeloma. Oncoscience
2017;4:73-4. DOI PubMed PMC
95. Fucci C, Resnati M, Riva E, et al. The interaction of the tumor suppressor FAM46C with p62 and FNDC3 proteins integrates protein
and secretory homeostasis. Cell Rep 2020;32:108162. DOI PubMed
96. Colla S, Ong DS, Ogoti Y, et al. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.
Cancer Cell 2015;27:644-57. DOI PubMed PMC
97. Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer 2017;3:506-28. DOI
PubMed
98. Marchesini M, Ogoti Y, Fiorini E, et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple
myeloma. Cancer Cell 2017;32:88-100.e6. DOI PubMed PMC
99. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature 2008;454:226-31. DOI PubMed PMC
100. Greenberg AJ, Walters DK, Kumar SK, Rajkumar SV, Jelinek DF. Responsiveness of cytogenetically discrete human myeloma cell
lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. Eur J Haematol
2013;91:504-13. DOI PubMed PMC